title: Update on therapy for chronic myelogenous leukemia.
abstract: Chronic myelogenous leukemia is a clonal disorder of hematopoietic stem cells characterized by granulocytic leukocytosis, splenomegaly, and a specific chromosomal abnormality, the Philadelphia chromosome. Treatment options include the oral agents hydroxyurea or busulfan, subcutaneous interferon-alpha, and bone marrow transplantation. The recent publication of some large, randomized trials and the increased availability of bone marrow transplantation are changing the therapeutic approach to chronic myelogenous leukemia. This paper reviews these recent studies on the management of chronic myelogenous leukemia.
authors.affiliation: LSU Medical Center, Shreveport.
authors.forename: B B
authors.initials: BB
authors.lastname: Weinberger
mesh_terms: D016026:Bone Marrow Transplantation; D002066:Busulfan / Q000627:therapeutic use; D006648:Histocompatibility; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D016898:Interferon-alpha / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy*
chemical_list: D016898:Interferon-alpha; D002066:Busulfan; D006918:Hydroxyurea